Rescheduling Hydrocodone Combination Products: Lessons from New York State

Published Online: Friday, January 24, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.
 
This is the eighth in a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)
 
These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
A Maine pharmacy tech has pleaded guilty to stealing drugs and falsifying records, after he was caught on camera taking handfuls of pills.
When a would-be robber entered a pharmacy in Wyoming with what looked like a real gun, a pharmacist behind the counter reached for his firearm and injured the suspect by shooting him, according to the Wyoming Tribune Eagle.
A man who stole a doctor’s notepad to write himself prescriptions is facing 52 charges, including identity theft and forgery.
Latest Issues
$auto_registration$